标题 |
Oral iptacopan monotherapy maintains efficacy and safety over 48 weeks in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) in the phase iii appoint-PNH trial
在iii期appoint-PNH试验中,口服iptacopan单药治疗在48周内维持了补体抑制剂初治的阵发性睡眠性血红蛋白尿症(PNH)患者的疗效和安全性
|
网址 | |
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
求助人 | |
下载 |